Skip to main content
Journal cover image

Does Angiosarcoma of the Breast Need Nodal Staging?

Publication ,  Journal Article
Herb, J; Maduekwe, UN; Goel, N; Rosenberger, LH; Spanheimer, PM
Published in: J Am Coll Surg
May 1, 2022

BACKGROUND: Breast angiosarcoma is a rare malignancy classically associated with hematogenous metastases. We sought to determine the prevalence of pathologic nodal involvement in patients with nonmetastatic, resected breast angiosarcoma and its association with overall survival. STUDY DESIGN: The National Cancer Database was used to identify patients with nonmetastatic angiosarcoma of the breast who underwent surgical resection from 2004 to 2017. The prevalence of regional lymph node operation and nodal positivity was calculated. The Kaplan-Meier method was used to evaluate overall survival among node-positive and node-negative patients. Cox proportional hazard modeling was used to evaluate the adjusted association of nodal positivity with overall survival. RESULTS: We included 991 patients with angiosarcoma. The median age was 69 years (interquartile range 57 to 78), and the cohort was 99% female. A total of 298 patients (30%) had pathologic regional nodal evaluation. Of those, 15 (5.0%) had positive regional lymph nodes. Node-positive patients had significantly worse survival than patients with negative regional lymph nodes. After adjusting for patient, tumor, and treatment factors, a positive regional lymph node was associated with worse overall survival compared with patients with no nodal evaluation (hazard ratio 3.20; 95% CI 1.75 to 5.86; p < 0.001). CONCLUSIONS: Patients with nonmetastatic angiosarcoma of the breast have a 5% regional lymph node positivity rate, which is at a common threshold to consider evaluation, and identifies patients with poor survival. A prospective study to determine performance characteristics of sentinel lymph node biopsy is warranted.

Duke Scholars

Published In

J Am Coll Surg

DOI

EISSN

1879-1190

Publication Date

May 1, 2022

Volume

234

Issue

5

Start / End Page

774 / 782

Location

United States

Related Subject Headings

  • Surgery
  • Sentinel Lymph Node Biopsy
  • Prospective Studies
  • Neoplasm Staging
  • Lymph Nodes
  • Lymph Node Excision
  • Humans
  • Hemangiosarcoma
  • Female
  • Breast Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Herb, J., Maduekwe, U. N., Goel, N., Rosenberger, L. H., & Spanheimer, P. M. (2022). Does Angiosarcoma of the Breast Need Nodal Staging? J Am Coll Surg, 234(5), 774–782. https://doi.org/10.1097/XCS.0000000000000131
Herb, Joshua, Ugwuji N. Maduekwe, Neha Goel, Laura H. Rosenberger, and Philip M. Spanheimer. “Does Angiosarcoma of the Breast Need Nodal Staging?J Am Coll Surg 234, no. 5 (May 1, 2022): 774–82. https://doi.org/10.1097/XCS.0000000000000131.
Herb J, Maduekwe UN, Goel N, Rosenberger LH, Spanheimer PM. Does Angiosarcoma of the Breast Need Nodal Staging? J Am Coll Surg. 2022 May 1;234(5):774–82.
Herb, Joshua, et al. “Does Angiosarcoma of the Breast Need Nodal Staging?J Am Coll Surg, vol. 234, no. 5, May 2022, pp. 774–82. Pubmed, doi:10.1097/XCS.0000000000000131.
Herb J, Maduekwe UN, Goel N, Rosenberger LH, Spanheimer PM. Does Angiosarcoma of the Breast Need Nodal Staging? J Am Coll Surg. 2022 May 1;234(5):774–782.
Journal cover image

Published In

J Am Coll Surg

DOI

EISSN

1879-1190

Publication Date

May 1, 2022

Volume

234

Issue

5

Start / End Page

774 / 782

Location

United States

Related Subject Headings

  • Surgery
  • Sentinel Lymph Node Biopsy
  • Prospective Studies
  • Neoplasm Staging
  • Lymph Nodes
  • Lymph Node Excision
  • Humans
  • Hemangiosarcoma
  • Female
  • Breast Neoplasms